Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Immunotherapy in Melanoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Immunotherapy in Melanoma

Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported...
Read More >>

Cemiplimab Explored in Advanced Basal Cell Carcinoma

Kirkwood Helped Chart Course of Adjuvant Immunotherapy in Melanoma

ESMO 2018: Engineered Anti-MAGE-A T-Cells Show Early Promise

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

Neoadjuvant Immunotherapy Emerges as a New Frontier

View More Stories >>

View Conference Coverage

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

2019 State of the Science Summit on Hematologic Malignancies in Seattle

15th International Conference on Malignant Lymphoma

2019 European Hematology Association Congress

2019 ASCO Annual Meeting

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

Dr. Tawbi on Checkpoint Inhibition in Melanoma

Dr. Eggermont Discusses Impact of Pembrolizumab in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Advances in Treating Melanoma: Closing Thoughts

COMBI-AD: Dual-Targeted Therapy for Stage 3 Melanoma

Alternative Approaches to Treating Melanoma

Emerging Agents and Combinations for Advanced Melanoma

Considering Chemotherapy's Value in Melanoma

Melanoma: Mechanisms of Resistance to Therapy

Targeting NRAS Mutations in Metastatic Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Less Common Side Effects With Immunotherapy in Melanoma

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

Immunotherapy-Related Pulmonary Toxicities in Melanoma

Melanoma: Management of Dermatologic Toxicities

Overall Toxicities With Immunotherapy in Melanoma

Monotherapy Versus Combination Therapy Approaches in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Metastatic Melanoma: The New Millennium

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now

Featured Video

Advances in BRAF-Targeted Therapy for Metastatic Melanoma

Novel Combination Approaches for Metastatic Kidney Cancer

Geoffrey Thomas Gibney, MD; Ryan J. Sullivan, MD; Hussein A. Tawbi, MD, discuss advances in BRAF-targeted therapy for patients with metastatic melanoma. View now

FDA Approvals in SCLC and of a Biosimilar, and Japanese Approvals in AML, Ovarian Cancer, and NTRK+ Tumors